AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes
Partnership aims to advance solutions to improve care pathways, clinical trial matching, safety monitoring, and guideline-directed care.
AstraZeneca and Oracle Health and Life Sciences today announced a unique collaboration to leverage AstraZeneca's scientific, clinical development and regulatory expertise with Oracle's real-world data, cloud infrastructure, and AI-enabled clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to accelerate clinical trial optimisation and help more patients receive the right care sooner.
Many serious conditions are diagnosed late; patients can wait a long time before they are referred and there are gaps in how we translate scientific advancements into clinical practice. This collaboration is designed to test practical ways to connect scientific research directly to clinical workflows and transform care. Initial areas of exploration include clinical trial recruitment, earlier diagnosis, drug-safety monitoring and leveraging real-world evidence across the lifecycle of a medicine. Programmes will span AstraZeneca's core disease areas including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare disease.
The collaboration will span multiple international projects with key regions including the US, Middle East, and Europe working with local governments and within applicable regulations to ensure these could be scaled in the future. The first programme will focus on supporting hypertension care and clinical research in Abu Dhabi, in partnership with healthcare company, M42. This will help clinical teams identify patients with uncontrolled hypertension; implementing guideline-directed care; and improving the recruitment for clinical trials.
Pascal Soriot, Chief Executive Officer, AstraZeneca said: "This unique collaboration brings leaders in healthcare and AI together at a global scale to accelerate the journey from the discovery of medicine to patient care. Combining AstraZeneca's world class science with Oracle's deep data and technology expertise, we can help clinicians identify patients sooner, optimise clinical trials, and generate evidence continuously across the lifecycle of a medicine."
Mike Sicilia, chief executive officer, Oracle said: "Some of the most important opportunities for AI are in healthcare, where better use of data can help turn scientific innovation into better outcomes for patients. By bringing AstraZeneca's scientific expertise together with Oracle's data, cloud, AI, and healthcare capabilities, we have an opportunity to help accelerate research, connect more patients to clinical trials, and ultimately bring relevant insights into care faster."
Anne-Claire Gerbaldi, Chief Digital, Data and AI Officer, AstraZeneca, said: "Too many patients are diagnosed late or face a long journey to get the care they need. To build the next decade of medicine, we aim to harness AI to connect learnings across science, clinical trials and everyday care, generating insights that continuously strengthen research, accelerate innovation, and enhance patient outcomes. Bringing together the unique capabilities of Oracle and AstraZeneca, we believe we can support smarter clinical trials, strengthen safety monitoring and help ensure patients are diagnosed sooner and receive the right care."
Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences, said: "Healthcare progress depends on shortening the distance between scientific insight and the decisions clinicians make every day. AstraZeneca brings deep scientific and therapeutic expertise, and Oracle will deliver the secure data, cloud, AI, and clinical workflow capabilities. This collaboration has the potential to help health systems identify eligible patients sooner, broaden access to clinical trials, and generate evidence that supports the next decision, all under the governance of the health systems delivering care."
The collaboration will use deidentified real-world data within robust governance, privacy and security arrangements. AstraZeneca will not receive patient-identifiable information. Each proposed project will be reviewed separately and will only proceed once appropriate legal, privacy, regulatory, ethical and institutional safeguards are in place. The companies have signed a non-binding term-sheet agreement. No financials are being disclosed as part of this agreement.
Notes
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.